Population pharmacokinetic modeling of Sepantronium bromide (YM155), a small molecule survivin suppressant, in patients with non-small cell lung cancer, hormone refractory prostate cancer, or unresectable stage III or IV melanoma

Investigational New Drugs

Volumn 31, Issue 2, 2013, Pages 443-451

  Aoyama, Yumiko ^a   Kaibara, Atsunori ^a   Takada, Akitsugu ^a   Nishimura, Tetsuya ^a   Katashima, Masataka ^a   Sawamoto, Taiji ^a  

^a ASTELLAS PHARMA INC   (Japan)

Author keywords

Hormone refractory prostate cancer; Non small cell lung cancer; Population pharmacokinetics; Sepantronium bromide; Unresectable stage III or IV melanoma; YM155

Indexed keywords

ALANINE AMINOTRANSFERASE; ALBUMIN; ASPARTATE AMINOTRANSFERASE; SEPANTRONIUM BROMIDE;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALBUMIN BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CANCER STAGING; CARDIOVASCULAR DISEASE; CASTRATION RESISTANT PROSTATE CANCER; CONTINUOUS INFUSION; CONTROLLED STUDY; CREATININE BLOOD LEVEL; CREATININE CLEARANCE; DRUG EFFICACY; DRUG ELIMINATION; DRUG SAFETY; FEMALE; HUMAN; HUMAN CELL; KIDNEY DISEASE; KIDNEY DYSFUNCTION; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MELANOMA; PRIORITY JOURNAL; TREATMENT DURATION; TREATMENT RESPONSE;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, NON-SMALL-CELL LUNG; DOSE-RESPONSE RELATIONSHIP, DRUG; ETHNIC GROUPS; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMIDAZOLES; INFUSIONS, INTRAVENOUS; INHIBITOR OF APOPTOSIS PROTEINS; JAPAN; LUNG NEOPLASMS; MALE; MAXIMUM TOLERATED DOSE; MELANOMA; MIDDLE AGED; MODELS, BIOLOGICAL; NAPHTHOQUINONES; NEOPLASM STAGING; NEOPLASMS, HORMONE-DEPENDENT; PROGNOSIS; PROSTATIC NEOPLASMS; TISSUE DISTRIBUTION;

EID: 84879553960     PISSN: 01676997     EISSN: 15730646     Source Type: Journal    
DOI: 10.1007/s10637-012-9867-x     Document Type: Article

References (22)

1. Ambrosini G, Adida C, Altieri DC (1997) A novel anti-apoptosis gene, survivin, expressed in cancer and lymphoma. Nat Med 3:917-21
2. Tamm I, Wang Y, Sausville E, et al. (1998) IAP-family protein survivin inhibits caspase activity and apoptosis induced by Fas (CD95), Bax, caspases, and anticancer drugs. Cancer Res 58:5315-5320
3. cdc2 phosphorylation of survivin. Proc Natl Acad Sci USA 97:13103-13107
4. Lu CD, Altieri DC, Tanigawa N (1998) Expression of a novel antiapoptosis gene, survivin, correlated with tumor cell apoptosis and p53 accumulation in gastric carcinomas. Cancer Res 58:1808-1812
5. + cells by hematopoietic growth factors: implication of survivin expression in normal hematopoiesis. Blood 98:2091-2100
6. Nakahara T, Takeuchi M, Kinoyama I, et al. (2007) YM155, a novel small-molecule survivin suppressant, induces regression of established human hormone-refractory prostate tumor xenografts. Cancer Res 67:8014-8021
7. Nakahara T, Kita A, Yamanaka K, et al. (2011) Broad spectrum and potent antitumor activities of YM155, a novel small-molecule survivin suppressant, in a wide variety of human cancer cell lines and xenograft models. Cancer Sci 102:614-621
8. Nakahara T, Yamanaka K, Hatakeyama S, et al. (2011) YM155, a novel survivin suppressant, enhances taxane-induced apoptosis and tumor regression in a human Calu 6 lung cancer xenograft model. Anti-cancer Drugs 22:454-462
9. Kita A, Nakahara T, Yamanaka K, et al. (2011) Antitumor effects of YM155, a novel survivin suppressant, against human aggressive non-Hodgkin lymphoma. Leukemia Res 35:787-792
10. Tolcher AW, Mita A, Lewis LD, et al. (2008) Phase I and pharmacokinetic study of YM155, a small-molecule inhibitor of survivin. J Clin Oncol 26:5198-5203
11. Giaccone G, Zatloukal P, Roubec J, et al. (2009) Multicenter phase II trial of YM155, a small-molecule suppressor of survivin, in patients with advanced, refractory, non-small-cell lung cancer. J Clin Oncol 27:4481-4486
12. Karavasilis V, Mita A, Hudes G, et al. (2007) Phase II monotherapy study of YM155, a novel survivin suppressant, administered by 168-hour continuous infusion in previously treated hormone refractory prostate cancer (HRPC). J Clin Oncol 25(June 20 Supplement):5135
13. Lewis KD, Samlowski W, Ward J, et al. (2009) A multi-center phase II evaluation of the small molecule survivin suppressor YM155 in patients with unresectable stage III or IV melanoma. Invest New Drugs 29:161-166
14. Cheson BD, Vose JM, Bartlett NL, et al. (2009) Safety and efficacy of YM155 in diffuse large B-cell lymphoma (DLBCL). J Clin Oncol 27 (suppl) abstr 8502
15. Tolcher AW, Papadopoulos K, Patnaik A, et al. (2009) Phase I/II open-label study of YM155 plus docetaxel and prednisone in men with hormone refractory prostate cancer (HRPC). ASCO Genitourinary Cancers Symposium Abstract 214
16. Kelly RJ, Rajan A, Chun G, Lopez-Chavez A, Giaccone G (2011) A phase 1 study of paclitaxel, carboplatin, and YM155 (survivin suppressor) in subjects with solid tumors. J Clin Oncol 29 (suppl) abstr 3090
17. Satoh T, Okamoto I, Miyazaki M, et al. (2009) Phase I Study of YM155, a novel survivin suppressant, in patients with advanced solid tumors. Clin Cancer Res 15:3872-3880
18. Beal SL, Sheinner LB, Boeckmann AJ, et al. (2006) NONMEM users guide: Part I-VII, (1989-2006). Icon Development Solutions, Ellicott City
19. Oken MM, Creech RH, Tormey DC, et al. (1982) Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 5:649-655
20. Cockcroft DW, Gault MH (1976) Prediction of creatinine clearance from serum creatinine. Nephron 16:31-41
21. Ette EI, Williams PJ, Kim YH, et al. (2003) Model appropriateness and population pharmacokientics modeling. J Clin Pharamacol 43:610-623
22. Food and Drug Administration (1999) Guidance for industry: population pharmacokientics. Food and Drug Administration, Rockville